| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
MINIREVIEW
1Department of Medical Physiology, The Panum Institute, University of Copenhagen, DK-2200 Copenhagen N; 2Department of Pharmacology, University of Aarhus, DK-8000 Aarhus C, Denmark; and 3Lilly Research Laboratories, D-22419 Hamburg, Germany
Submitted 2 December 2003 ; accepted in final form 2 February 2004
The available evidence suggests that about two-thirds of the insulin response to an oral glucose load is due to the potentiating effect of gut-derived incretin hormones. The strongest candidates for the incretin effect are glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). In patients with type 2 diabetes, however, the incretin effect is lost or greatly impaired. It is hypothesized that this loss explains an important part of the impaired insulin secretion in patients. Further analysis of the incretin effects in patients has revealed that the secretion of GIP is near normal, whereas the secretion of GLP-1 is decreased. On the other hand, the insulintropic effect of GLP-1 is preserved, whereas the effect of GIP is greatly reduced, mainly because of a complete loss of the normal GIP-induced potentiation of second-phase insulin secretion. These two features, therefore, explain the incretin defect of type 2 diabetes. Strong support for the hypothesis that the defect plays an important role in the insulin deficiency of patients is provided by the finding that administration of excess GLP-1 to patients may completely restore the glucose-induced insulin secretion as well as the 
-cells' sensitivity to glucose. Because of this, analogs of GLP-1 or GLP-1 receptor activations are currently being developed for diabetes treatment, so far with very promising results.
glucose-dependent insulinotropic polypeptide; glucagon-like peptide 1; diabetes
This article has been cited by other articles:
|
|
 |
|
  R. K. Campbell and S. Miller New Therapeutic Horizons: Mapping the Future of Glycemic Control With Incretin-based Therapy The Diabetes Educator, September 1, 2009; 35(5): 731 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. DeFronzo From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus Diabetes, April 1, 2009; 58(4): 773 - 795. [Full Text] [PDF]
|
|
|
|
 |
|
 R L Young, K Sutherland, N Pezos, S M Brierley, M Horowitz, C K Rayner, and L A Blackshaw Expression of taste molecules in the upper gastrointestinal tract in humans with and without type 2 diabetes Gut, March 1, 2009; 58(3): 337 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-S. Lu, Y.-L. Yu, H.-J. Zhu, X.-D. Liu, L. Liu, Y.-W. Liu, P. Wang, L. Xie, and G.-J. Wang Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats J. Endocrinol., February 1, 2009; 200(2): 159 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Vrbikova, M. Hill, B. Bendlova, T. Grimmichova, K. Dvorakova, K. Vondra, and G. Pacini Incretin levels in polycystic ovary syndrome Eur. J. Endocrinol., August 1, 2008; 159(2): 121 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L R Ranganath Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 J. Clin. Pathol., April 1, 2008; 61(4): 401 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Weksler-Zangen, I. Raz, S. Lenzen, A. Jorns, S. Ehrenfeld, G. Amir, A. Oprescu, Y. Yagil, C. Yagil, D. H. Zangen, et al. Impaired Glucose-Stimulated Insulin Secretion Is Coupled With Exocrine Pancreatic Lesions in the Cohen Diabetic Rat Diabetes, February 1, 2008; 57(2): 279 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Karamanlis, R. Chaikomin, S. Doran, M. Bellon, F D. Bartholomeusz, J. M Wishart, K. L Jones, M. Horowitz, and C. K Rayner Effects of protein on glycemic and incretin responses and gastric emptying after oral glucose in healthy subjects Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1364 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Pilichiewicz, R. Chaikomin, I. M. Brennan, J. M. Wishart, C. K. Rayner, K. L. Jones, A. J. P. M. Smout, M. Horowitz, and C. Feinle-Bisset Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E743 - E753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Xu, H. Kaneto, D. R. Laybutt, V. F. Duvivier-Kali, N. Trivedi, K. Suzuma, G. L. King, G. C. Weir, and S. Bonner-Weir Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia: Possible Contribution to Impaired Incretin Effects in Diabetes Diabetes, June 1, 2007; 56(6): 1551 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Aschner, M. S. Kipnes, J. K. Lunceford, M. Sanchez, C. Mickel, D. E. Williams-Herman, and for the Sitagliptin Study 021 Group Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes Diabetes Care, December 1, 2006; 29(12): 2632 - 2637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hinnen, L. L. Nielsen, A. Waninger, and P. Kushner Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes J Am Board Fam Med, November 1, 2006; 19(6): 612 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Cani, C. Knauf, M. A. Iglesias, D. J. Drucker, N. M. Delzenne, and R. Burcelin Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like Peptide 1 receptor. Diabetes, May 1, 2006; 55(5): 1484 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N Friedrichsen, N. Neubauer, Y. C Lee, V. K Gram, N. Blume, J. S Petersen, J. H Nielsen, and A. Moldrup Stimulation of pancreatic {beta}-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J. Endocrinol., March 1, 2006; 188(3): 481 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E Laaksonen, L. K Toppinen, K. S Juntunen, K. Autio, K.-H. Liukkonen, K. S Poutanen, L. Niskanen, and H. M Mykkanen Dietary carbohydrate modification enhances insulin secretion in persons with the metabolic syndrome Am. J. Clinical Nutrition, December 1, 2005; 82(6): 1218 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Nikolaidis, D. Elahi, Y.-T. Shen, and R. P. Shannon Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2401 - H2408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Comi Treatment of Type 2 Diabetes Mellitus: A Weighty Enigma Ann Intern Med, October 18, 2005; 143(8): 609 - 610. [Full Text] [PDF]
|
|
|
|
|
|
S. Seino and T. Shibasaki PKA-Dependent and PKA-Independent Pathways for cAMP-Regulated Exocytosis Physiol Rev, October 1, 2005; 85(4): 1303 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Gault, N. Irwin, B. D. Green, J. T. McCluskey, B. Greer, C. J. Bailey, P. Harriott, F. P.M. O'Harte, and P. R. Flatt Chemical Ablation of Gastric Inhibitory Polypeptide Receptor Action by Daily (Pro3)GIP Administration Improves Glucose Tolerance and Ameliorates Insulin Resistance and Abnormalities of Islet Structure in Obesity-Related Diabetes Diabetes, August 1, 2005; 54(8): 2436 - 2446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Del Prato, R. Miccoli, and G. Penno Review: The importance of effective early phase insulin secretion The British Journal of Diabetes & Vascular Disease, July 1, 2005; 5(4): 198 - 202. [Abstract] [PDF]
|
|
|
|
|
|
D. M. Kendall, M. C. Riddle, J. Rosenstock, D. Zhuang, D. D. Kim, M. S. Fineman, and A. D. Baron Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea Diabetes Care, May 1, 2005; 28(5): 1083 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. DeFronzo, R. E. Ratner, J. Han, D. D. Kim, M. S. Fineman, and A. D. Baron Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes Diabetes Care, May 1, 2005; 28(5): 1092 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Holst and C. Orskov The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism Diabetes, December 1, 2004; 53(suppl_3): S197 - S204. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
